European Surveillance of Antimicrobial Consumption (ESAC): outpatient antimycotic use in Europe
Abstract number: P1734
Adriaenssens N., Coenen S., Muller A., Vankerckhoven V., Hendrickx E., Goossens H.
Objectives: To assess the total outpatient systemic antimycotic use in Europe and to identify the antimycotic substances most commonly used.
Methods: The European Surveillance of Antimicrobial Consumption (ESAC; www.esac.ua.ac.be) project, now funded by the European Center for Disease Control and Prevention (ECDC; agreement number 2007/001), continues to collect data on antimicrobial consumption for all Member States, candidate countries and European Free Trade Association-European Economic Area countries using the anatomic chemical therapeutic (ATC) classification and the defined daily dose (DDD) measurement unit. For 2007, data on outpatient use of all antimycotics for systemic use (ATC J02 and D01B), aggregated at the level of the active substance, was collected and use was expressed in DDD (WHO ATC/DDD, version 2007) per 1000 inhabitants per day (DID). Only countries for which data on both J02 and D01B use was available were included in the analysis.
Results: Total outpatient antimycotic use in 2007 in 11 European countries (data for Estonia include hospital use) varied by a factor of 11.65 between the country with the highest (3.03 DID in Belgium) and the country with the lowest (0.26 DID in Slovakia) use. Terbinafine, itraconazole, and fluconazole were the most prescribed substances, and represented more than 96% of the total outpatient antimycotic use in all countries except for Estonia, Slovakia and Latvia (83.8%, 78.5% and 74.6%, respectively). Terbinafine use represented more than 50% of the total outpatient antimycotic use in 8 out of 11 countries (not in Latvia, Hungary and Italy).
Figure: Total outpatient systemic antimycotic use in 11 European countries in 2007.
Conclusion: Our study demonstrates a variation of outpatient systemic antimycotic use in Europe as striking as that of outpatient systemic antibiotic use. The ESAC data facilitate auditing of antimycotic prescribing and evaluation of the implementation of guidelines and public health policies to promote its judicious use.
|Session name:||19th European Congress of Clinical Microbiology and Infectious Diseases|
|Location:||Helsinki, Finland, 16 - 19 May 2009|
|Back to top|